EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Colistin-resistance genes in Escherichia coli isolated from patients with urinary tract infections

Waleed M Al Momani iD, Nour Ata, Ahmed O Maslat

PLOS ONE · 12.06.2024 · 19 (6) · e0305431

DOI: 10.1371/journal.pone.0305431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 12.06.2024. Verfasst von Waleed M Al Momani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan. Hauptthemen laut MEDLINE: Colistin, Urinary Tract Infections, Escherichia coli, Anti-Bacterial Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence of antimicrobial resistance is alarmingly high because it occurs in humans, environment, and animal sectors from a “One Health” viewpoint. The emergence of plasmid-carried mobile colistin-resistance ( MCR ) genes limits the efficacy of colistin, which is the last-line treatment for multidrug resistance (MDR) against gram-negative infections.

Objectives

The current study aimed to investigate emergence of colistin-resistance ( MCR 1–5) genes in E . coli isolated from patients with urinary tract infections (UTIs) in Jordan.

Methods

E . coli (n = 132) were collected from urine specimens. The E . coli isolated from human UTI patients were examined the resistance to colistin based on the presence of MCR (1–5). All isolates were tested against 20 antimicrobials using the standard disk diffusion method. The broth microdilution technique was used to analyze colistin resistance. In addition, the MCR (1–5) genes were detected using multiplex PCR.

Results

Out of the 132 isolates, 1 isolate was colistin-resistant, having a minimum inhibitory concentration of 8 μg/mL and possessing MCR -1. All the E . coli isolates showed high resistance to penicillin (100%), amoxicillin (79.55%), cephalexin (75.76%), nalidixic acid (62.88%), tetracycline (58.33%), or cefepime (53.79).

Conclusion

To our knowledge, this is the first report on the presence of plasmid-coded MCR -1 in E . coli from a patient with UTIs in Jordan. This is a problematic finding because colistin is the last-line drug for the treatment of infections caused by MDR gram-negative bacteria. There is a crucial need to robustly utilize antibiotics to control and prevent the emergence and prevalence of colistin-resistance genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColistinUrinary Tract InfectionsEscherichia coliAnti-Bacterial AgentsMicrobial Sensitivity TestsEscherichia coli InfectionsHumansFemaleMaleAdultMiddle AgedEscherichia coli ProteinsDrug Resistance, BacterialAgedJordanAdolescentYoung AdultDrug Resistance, Multiple, BacterialPlasmidsChild

Substanzen

ColistinAnti-Bacterial AgentsEscherichia coli ProteinsMCR-1 protein, E coli

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan.
  • Department of Biological Sciences, Faculty of Science, Yarmouk University, Irbid, Jordan.

ORCID-Profile: Waleed M Al Momani

Zitieren

APA

Al Momani, W. M., Ata, N., & Maslat, A. O. (2024). Colistin-resistance genes in Escherichia coli isolated from patients with urinary tract infections. PLOS ONE, 19(6), e0305431. https://doi.org/10.1371/journal.pone.0305431

Vancouver

Al Momani WM, Ata N, Maslat AO. Colistin-resistance genes in Escherichia coli isolated from patients with urinary tract infections. PLOS ONE. 2024;19(6):e0305431. doi:10.1371/journal.pone.0305431

BibTeX
@article{AlMomani2024,
  author = {Al Momani, Waleed M and Ata, Nour and Maslat, Ahmed O},
  title = {Colistin-resistance genes in Escherichia coli isolated from patients with urinary tract infections},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {6},
  pages = {e0305431},
  doi = {10.1371/journal.pone.0305431}
}
Kostenlos starten →